KBL Merger Corp. IV Announces Special Meeting of Shareholders to be Held October 26, 2020 upon the SEC Declaring the S-4 Registration Statement Effective
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) — KBL Merger Corp. IV (NASDAQ: KBLM or the “Company”), a special purpose acquisition company (SPAC) that previously announced the acquisition of 180 Life Sciences Corp. (“180 Life Sciences”), today announced the registration statement on Form S-4 (File No. 333-234650) (as amended, the “Registration Statement”), filed by the Company relating to the previously announced business combination with 180 Life Sciences (the “Business Combination”), has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”).
The Company has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the “Special Meeting”) of the Company’s stockholders to be held on October 26, 2020 in connection with the Business Combination.The proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business on September 30, 2020.The Company previously announced that it had successfully closed a bridge financing, the proceeds of which will be used for working capital to complete the Business Combination and advance its clinical programs. At the conclusion of the financing, Dr. James Woody became Chief Executive Officer of 180 Life Sciences, and more recently the Company announced the addition of four new independent members to its board of directors effective upon the closing of the Business Combination, forming a world-class board of directors. Link to the announcement can be found here.180 Life Sciences is a clinical-stage biotech company developing three major drug platforms that treat inflammatory diseases and address large markets. The first platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in Phase 2b/3 and two additional clinical trials that are expected to begin after the completion of the merger. The second platform focuses on developing novel, orally available therapies harnessing synthetic endocannabinoid compounds and the identification of novel medications to treat chronic pain in diseases such as arthritis. The third platform, alpha 7 nicotinic acetylcholine receptor (“α7nAChR”), nicotine receptors is in progress to treat inflammatory diseases, initially ulcerative colitis induced after cessation of smoking.Additional Background on 180 Life Sciences Corp.180 Life Sciences’ three clinical programs address the following indications:Dupuytren’s contracture, a fibrotic disease of the hand, which is in Phase 2b/3, with results expected in Q1 2021. Frozen shoulder, with a grant to initiate the clinical study awarded by the National Institute of Health Research, U.K.Post-operative cognitive delirium disorder and dysfunction, a major unmet clinical need occurring in the elderly patient population, most commonly after hip fracture repair.
Additionally, 180 Life Sciences’ pre-clinical discovery programs include:A program focused on the development of unique, FDA-approved, pharmaceutical-grade cannabinoids to treat pain that is specifically focused on arthritis.The α7nAChR program which aims to develop α7nAChR agonists for the treatment of inflammatory diseases, initially ulcerative colitis induced after cessation of smoking
About KBL Merger Corp. IVAdditional Information about the Business Combination and Where to Find ItParticipants in SolicitationNon-SolicitationForward-Looking StatementsInvestors:Jason Assad
Director of IR
180 Life Sciences Corp
678-570-6791
Jason@180lifesciences.com
The Company has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the “Special Meeting”) of the Company’s stockholders to be held on October 26, 2020 in connection with the Business Combination.The proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business on September 30, 2020.The Company previously announced that it had successfully closed a bridge financing, the proceeds of which will be used for working capital to complete the Business Combination and advance its clinical programs. At the conclusion of the financing, Dr. James Woody became Chief Executive Officer of 180 Life Sciences, and more recently the Company announced the addition of four new independent members to its board of directors effective upon the closing of the Business Combination, forming a world-class board of directors. Link to the announcement can be found here.180 Life Sciences is a clinical-stage biotech company developing three major drug platforms that treat inflammatory diseases and address large markets. The first platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in Phase 2b/3 and two additional clinical trials that are expected to begin after the completion of the merger. The second platform focuses on developing novel, orally available therapies harnessing synthetic endocannabinoid compounds and the identification of novel medications to treat chronic pain in diseases such as arthritis. The third platform, alpha 7 nicotinic acetylcholine receptor (“α7nAChR”), nicotine receptors is in progress to treat inflammatory diseases, initially ulcerative colitis induced after cessation of smoking.Additional Background on 180 Life Sciences Corp.180 Life Sciences’ three clinical programs address the following indications:Dupuytren’s contracture, a fibrotic disease of the hand, which is in Phase 2b/3, with results expected in Q1 2021. Frozen shoulder, with a grant to initiate the clinical study awarded by the National Institute of Health Research, U.K.Post-operative cognitive delirium disorder and dysfunction, a major unmet clinical need occurring in the elderly patient population, most commonly after hip fracture repair.
Additionally, 180 Life Sciences’ pre-clinical discovery programs include:A program focused on the development of unique, FDA-approved, pharmaceutical-grade cannabinoids to treat pain that is specifically focused on arthritis.The α7nAChR program which aims to develop α7nAChR agonists for the treatment of inflammatory diseases, initially ulcerative colitis induced after cessation of smoking
About KBL Merger Corp. IVAdditional Information about the Business Combination and Where to Find ItParticipants in SolicitationNon-SolicitationForward-Looking StatementsInvestors:Jason Assad
Director of IR
180 Life Sciences Corp
678-570-6791
Jason@180lifesciences.com
